Free Trial
NASDAQ:SPRY

ARS Pharmaceuticals Q2 2023 Earnings Report

ARS Pharmaceuticals logo
$14.26 -0.20 (-1.38%)
Closing price 05/5/2025 04:00 PM Eastern
Extended Trading
$14.28 +0.02 (+0.11%)
As of 05/5/2025 04:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ARS Pharmaceuticals EPS Results

Actual EPS
-$0.18
Consensus EPS
-$0.17
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

ARS Pharmaceuticals Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ARS Pharmaceuticals Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Thursday, August 10, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

ARS Pharmaceuticals' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Wednesday, May 14, 2025 at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

ARS Pharmaceuticals Earnings Headlines

3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
ARS Pharmaceuticals Has A Blockbuster Candidate
See More ARS Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ARS Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ARS Pharmaceuticals and other key companies, straight to your email.

About ARS Pharmaceuticals

ARS Pharmaceuticals (NASDAQ:SPRY), a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

View ARS Pharmaceuticals Profile

More Earnings Resources from MarketBeat